# Journey Medical Corporation to Participate in A.G.P.’s Annual Virtual Healthcare Conference
Canonical URL: https://biopharmsignal.com/news/DERM/journey-medical-corporation-to-participate-in-a-g-p-s-annual-virtual-healthcare-conference
Ticker: DERM
Company: Journey Medical Corporation
Source: Journey Medical Corporation
Published: 2026-06-25 13:46 EST
Original Source URL: https://ir.journeymedicalcorp.com
## Summary

SCOTTSDALE, Ariz., May 19, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical,” “the Company,”…...

## Article Body
SCOTTSDALE, Ariz., May 19, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical,” “the Company,” “we” or “our”), a commercial-stage pharmaceutical company focused on developing, selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that Claude Maraoui, Co-Founder, President and Chief Executive Officer, will participate in a fireside chat at A.G.P.’s Annual Virtual Healthcare Conference, taking place on Wednesday, May 20, 2026. The fireside chat is scheduled to begin at 5:00pm ET.

To register for the conference, visit the A.G.P. Registration Link .

About Journey Medical Corporation Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”) is a commercial-stage pharmaceutical company that primarily focuses on developing, selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions through its efficient sales and marketing model. The Company currently markets eight branded FDA-approved prescription drugs that help treat and heal common skin conditions. The Journey Medical team comprises industry experts with extensive experience in developing and commercializing some of dermatology’s most successful prescription brands. Journey Medical is located in Scottsdale, Arizona and was founded by Fortress Biotech, Inc. (Nasdaq: FBIO). Journey Medical’s common stock is registered under the Securities Exchange Act of 1934, as amended, and it files periodic reports with the U.S. Securities and Exchange Commission (“SEC”). For additional information about Journey Medical, visit www.journeymedicalcorp.com .

Company Contact: Jaclyn Jaffe (781) 652-4500 ir@jmcderm.com

Media Relations Contact: Tony Plohoros 6 Degrees (908) 591-2839 tplohoros@6degreespr.com

Source: Journey Medical Corporation Released May 19, 2026
## Recent Company News
- 2026-06-25 13:46 EST — [Journey Medical Corporation Reports First Quarter 2026 Financial Results and Recent Corporate Highlights](https://biopharmsignal.com/news/DERM/journey-medical-corporation-reports-first-quarter-2026-financial-results-and-recent-corporate-highlights) — Source: Journey Medical Corporation
- 2026-06-25 13:46 EST — [Journey Medical Corporation to Announce First Quarter 2026 Financial Results on May 13, 2026](https://biopharmsignal.com/news/DERM/journey-medical-corporation-to-announce-first-quarter-2026-financial-results-on-may-13-2026) — Source: Journey Medical Corporation
- 2026-06-25 13:46 EST — [Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights](https://biopharmsignal.com/news/DERM/journey-medical-corporation-reports-full-year-2025-financial-results-and-recent-corporate-highlights) — Source: Journey Medical Corporation
- 2026-06-25 13:46 EST — [Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026](https://biopharmsignal.com/news/DERM/journey-medical-corporation-to-announce-year-end-2025-financial-results-on-march-25-2026) — Source: Journey Medical Corporation
- 2026-06-25 13:46 EST — [Journey Medical Corporation to Participate in A.G.P.’s Annual Virtual Healthcare Conference](https://biopharmsignal.com/news/DERM/journey-medical-corporation-to-participate-in-a-g-p-s-annual-virtual-healthcare-conference) — Source: Journey Medical Corporation
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)